Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first-line metastatic pancreatic cancer (MPC): Updated results
Picozzi, Vincent J., Lin, Bruce Shih-Li, Mandelson, Margaret T.
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article
Treatment dependent improvements in survival of stage 2/3 rectal cancer patients treated with trimodality therapy between 2006-2016, an NCDB analysis
Kennecke, Hagen Fritz, Bahnson, Henry T., Lin, Bruce Shih-Li, Kaplan, Jennifer, Pham, Huong, Suen, Andrew, Simianu, Val
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma
Maithel, Shishir K., Javle, Milind M., Mahipal, Amit, Lin, Bruce Shih-Li, Akce, Mehmet, Switchenko, Jeffrey M., Rupji, Manali, Tran Cao, Hop, Cleary, Sean P., Rocha, Flavio G.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03)
Sahai, Vaibhav, Griffith, Kent A., Lin, Bruce Shih-Li, Soares, Heloisa P., Chandana, Sreenivasa R, Crysler, Oxana V., Enzler, Thomas, Zalupski, Mark
Published in Journal of clinical oncology (01.02.2022)
Published in Journal of clinical oncology (01.02.2022)
Get full text
Journal Article
Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis
Picozzi, Vincent J., Mandelson, Margaret T., Lin, Bruce Shih-Li, Biehl, Thomas R, Alseidi, Adnan, Rocha, Flavio G., Helton, Scott
Published in Journal of clinical oncology (01.02.2020)
Published in Journal of clinical oncology (01.02.2020)
Get full text
Journal Article
A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma
Dayyani, Farshid, Baretti, Marina, Lee, Sunyoung S., He, Aiwu Ruth, Kim, Richard D., Lin, Bruce Shih-Li, Enzler, Thomas, Al Hallak, Mohammed Najeeb, Ulahannan, Susanna Varkey, Davis, S. Lindsey, Burgoyne, Adam, Tweardy, David, Harding, James J., Kaseb, Ahmed Omar, de Achaval, Sofia, Alibhai, Imran, Kauh, John S.
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas
Kelly, Ronan Joseph, Abrams, Thomas Adam, Catenacci, Daniel V.T., Wainberg, Zev A., Lin, Bruce Shih-Li, Enstrom, Amanda, Whiting, Chan C., Wason, Prieya, Murphy, Aimee, Brockstedt, Dirk G., Moon, Anne, Walling, Jackie, Lai, Rose, Ku, Geoffrey Yuyat
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Initial gemcitabine/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): The SEENA-1 study
Picozzi, Vincent J., Leach, Joseph W., Seng, John E., Anthony, Stephen Patrick, Mena, Raul, Larson, Tim, Borazanci, Erkut Hasan, Weiss, Glen J., Lin, Shih-Li Bruce, Jameson, Gayle S., Bolejack, Vanessa, Stoll, Amy C., Von Hoff, Daniel D., Ramanathan, Ramesh K.
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article